ELAB Elevai Labs Inc

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 29, 2024

 

Elevai Labs Inc.

(Exact name of registrant as specified in its charter)

 

Delaware		001-41875		85-1399981
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

 

c/o 120 Newport Center Drive, Ste. 250 Newport Beach, CA		92660
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code: (866) 794-4940

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		ELAB		The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On June 29, 2024, representatives of Elevai Labs Inc. (the “Company”) began presenting and distributing a presentation slide containing the information attached to this Current Report on Form 8-K as Exhibit 99.1 (the “Presentation”) and incorporated herein by reference, at the National Hair Loss Medical Aesthetics conference, and intends to, from time to time, present and distribute the Presentation to the investment community and utilize the Presentation at various conferences.

 

The information contained in the Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.

 

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

 

Forward Looking Statements

 

This Current Report on Form 8-K, including Exhibits 99.1 hereto, contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should” or similar expressions, although some forward-looking statements are expressed differently. Forward-looking statements represent the Company’s management’s judgment regarding future events. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. All statements other than statements of historical fact included in the Current Report on Form 8-K are forward-looking statements. The Company cannot guarantee the accuracy of the forward-looking statements, and you should be aware that the Company’s actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including the statements under “Risk Factors” contained in the Company’s reports filed with the SEC.

 

Item 9.01 Financial Statements and Exhibits. 

 

(d) Exhibits. 

 

The following exhibits are being filed herewith: 

 

Exhibit No.		Description
99.1*		Slide Presentation of the Company dated as of June 29, 2024.
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

 

*	Furnished herewith.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: September 4, 2024

 

Elevai Labs, Inc.
By:	/s/ Graydon Bensler
Name:	Graydon Bensler
Title:	Chief Executive Officer, President and Director

 

 

2

 

Exhibit 99.1

 

Nation a N l Hair loss Medical Aesthetics President Carly Klein

Today the #1 leading cause of Alopecia is Genetics While hair loss is a common affliction for both men and women, there are two underlying causes, and symptoms can vary widely. An important aspect of successfully treating hair loss is addressing the underlying factor to blame.

Miniaturizing Process

Growt h Cycles Think of a hair bulb as a seed, once that seed is planted deep enough the dermal papillae starts to provide nourishment like an umbilical cord . Shaft continues to grow upward/outward until the new shaft pushes the old shaft out • Anagen Phase • Catagen Phase • Telogen Phase Hair doesn't grow all at once, each strand is constantly undergoing 1 of 3 phases. + If the dermal papilla fails to make connection the hair will not continue to grow Once the active growth cycle is over - the transitional phase between growth and resting takes place this lasts normal a few days to a few weeks, sometimes longer periods due to illnesses. 3rd phase of the cycle - this last usually 3 - 5 months this final life cycle causes the hair to cease growing enters a resting state where it hibernates - not getting any supply of nutrition to the hair since its fully grown

Androgenetic Alopecia micros In this photo we can see miniaturization of hair follicles which indicates that this client has androgenetic alopecia.

Exosomes Exosomes are tiny communication vesicles, produced by stem cells that give the incredible power to help rejuvenate the tissue. Proteins delivered in the exosomes provide cellular communications that signal healing anti - inflammatory responses and cellular growth. Exosomes can be utilized in the early to late stages of hair loss, and additionally it can be used in combination with transplants and PRP.

3 Month Results 72 year old Female • ELEVAI Empower Exosome Treatment following microneedling every 4 weeks • At Home ELEVAI Topical Exosomes with daily application in areas of concern

3 Month Results 29 year old Female • 2 Empower Treatments: Microneedling followed by application of ELEVAI Exosomes (~6 weeks apart) • At Home ELEVAI Exosome Topical: Daily topical application in concerned areas

At the Hairline Baseline: We can see miniaturization of hair follicles that are almost gone. After: You can see the pigmentation has changed and the hair is stronger. More hairs per sq. cm doesn’t always mean new growth - - this can be a large number of hairs recovered from the dormant phase.

1 Year Results 38 year old Male • In office Treatments: Microneedling with ELEVAI Empower every 8 weeks • At Home ELEVAI exosome Topical: Regiment of daily topical application in areas of concern

We see also in the crown inflammation ceased reversal of miniaturized hairs In this photo of the hair line, we can see miniaturization of hair follicles, pitting where we have active inflammation . Now we see the pitting has closed up the hair is stable. Baseline Baseline HAIRLINE CROWN After After

Rooted in nature, perfected by science.

The ELEVAI Root Renewal System

E L E V A I S - S E R I E S 07 / 10 This innovative dual mechanism of action approach targets the hair root and works synergistically to achieve visual improvements in hair growth thickness and density while reducing the appearance of hair shedding and thinning hair. • PREx , Precision Regenerative Exosome Technology • YuvaBio Y100, a small molecule discovered using AI that supports mitochondrial function restoration.

ELEVAI Root Renewal System • •

Jordan R. Plews, Ph.D. Co - Founder & CEO, ELEVAI Skincare Nasdaq: ELAB contact @elevaiskincare.com Carly Klein President, NHLMA education@nhlma.com NHLMA.com

v3.24.2.u1

Cover	Jun. 29, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 29, 2024
Entity File Number	001-41875
Entity Registrant Name	Elevai Labs Inc.
Entity Central Index Key	0001840563
Entity Tax Identification Number	85-1399981
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	c/o 120 Newport Center Drive
Entity Address, Address Line Two	Ste. 250
Entity Address, City or Town	Newport Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92660
City Area Code	866
Local Phone Number	794-4940
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	ELAB
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

---